Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs
- 1 March 1995
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 18 (3) , 207-231
- https://doi.org/10.1016/1040-8428(94)00131-c
Abstract
No abstract availableThis publication has 108 references indexed in Scilit:
- Sterically stabilized liposomesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1992
- Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compoundsEuropean Journal of Cancer and Clinical Oncology, 1991
- Neoglycoproteins as Carriers for Receptor‐Mediated Drug Targeting in the Treatment of Experimental Visceral LeishmaniasisThe Journal of Protozoology, 1990
- Sugar receptor mediated drug delivery to macrophages in the therapy of experimental visceral leishmaniasisBiochemical and Biophysical Research Communications, 1990
- Monensin is obligatory for the cytotoxic action of a disulfide linked methotrexate-anti-transferrin receptor conjugateBiochemical and Biophysical Research Communications, 1988
- Anthracycline antitumour agentsInternational Journal of Clinical Pharmacy, 1986
- Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary reportEuropean Journal of Cancer and Clinical Oncology, 1983
- Cis-aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugateBiochemical and Biophysical Research Communications, 1981
- Melanotropin–daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cellsNature, 1977
- Animal scale-upJournal of Pharmacokinetics and Biopharmaceutics, 1973